NCT05963347View on ClinicalTrials.gov

Go-CHOP as the Frontline Therapy for PTCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

August 3, 2023

Primary Completion Date

July 30, 2025

Study Completion Date

July 31, 2026

Conditions
Peripheral T Cell Lymphoma
Interventions
DRUG

Golidocitinib

Daily dose. Starting dose of golidocitinib is 75 mg QD. If tolerated, subsequent cohorts will test ascending doses of golidocitinib.

DRUG

CHOP Regimen

CHOP will be administered in a 21-day cycle for a maximum of 6 cycles.

Trial Locations (1)

450008

RECRUITING

Henan Cancer Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV